title: Formulation and evaluation of irinotecan suppository for rectal administration.
abstract: Irinotecan suppository was prepared using the moulding method with a homogeneous blend. A sensitive and specific fluorescence method was developed and validated for the determination of irinotecan in plasma using HPLC. The pharmacokinetics of intravenous administered and rectal administered in rabbits was investigated. Following a single intravenous dose of irinotecan (50 mg/kg), the plasma irinotecan concentration demonstrated a bi-exponential decay, with a rapid decline over 15 min. Cmax, t1/2, AUC0-30h and AUC0-∞ were 16.1 ± 2.7 g/ml, 7.6 ± 1.2 h, 71.3 ± 8.8 μg·h/ml and 82.3 ± 9.5 μg·h/ml, respectively. Following rectal administration of 100 mg/kg irinotecan, the plasma irinotecan concentration reached a peak of 5.3 ± 2.5 μg/ml at 4 h. The AUC0-30h and AUC0-∞ were 32.2 ± 6.2 μg·h/ml and 41.6 ± 7.2 μg·h/ml, respectively. It representing ∼50.6% of the absolute bioavailability.
authors.affiliation: Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou 310-022, China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Feng
authors.affiliation: Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou 310-022, China.
authors.forename: Yuping
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou 310-022, China.
authors.forename: Dechuan
authors.initials: D
authors.lastname: Li
keywords: HPLC; Irinotecan; Oral; Pharmacokinetics; Rectal